Phone Number: 92********
Who is ELYSIUM THERAPEUTICS
Elysiums mission is to reduce suffering from severe acute pain, opioid-use disorder (OUD), and fatal opioid overdose by developing first- or best-in-class products with profiles that addr...
Read More
- Headquarters: Akron, Ohio, United States
- Date Founded: 2013
- Employees: 1-10
- Revenue: $1 Million to $5 Million
- Active Tech Stack: See technologies
- CEO: Alex Sturmer
Industry: Biotechnology
SIC Code: 2834
Does something look wrong? Fix it. | View contact records from ELYSIUM THERAPEUTICS
Elysium Therapeutics Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Elysium Therapeutics
Answer: Elysium Therapeutics's headquarters are located at Akron, Ohio, United States
Answer: Elysium Therapeutics's phone number is 92********
Answer: Elysium Therapeutics's official website is https://elysiumrx.com
Answer: Elysium Therapeutics's revenue is $1 Million to $5 Million
Answer: Elysium Therapeutics's SIC: 2834
Answer: Elysium Therapeutics has 1-10 employees
Answer: Elysium Therapeutics is in Biotechnology
Answer: Elysium Therapeutics contact info: Phone number: 92******** Website: https://elysiumrx.com
Answer: Elysiums mission is to reduce suffering from severe acute pain, opioid-use disorder (OUD), and fatal opioid overdose by developing first- or best-in-class products with profiles that address the key limitations and dangers associated with opioids used today. Our pipeline consists of 3 diverse platforms with broad applicability across several areas of significant unmet need: Technologies 1. O2PTM (Oral Overdose Protection) Lead platform Traditional opioids are easy to abuse, with euphoria and risk of respiratory depression increasing with every pill consumed. O2P provides self-limiting exposure to active opioid and prevents overdose. 2. XpiRxTM (Forced Expiration) 70-year half-life of traditional opioids creates a surplus supply of readily available pills that can end up on the streets. XpiRx opioids, whose potency expires after the prescribed-use period, reduce abuse and prevent fatal overdoses. 3. SOOPRTM (Synthetic Opioid Overdose Prevention and Rescue) Existing rescue agents are too short-acting and weak against synthetic opioids, often requiring multiple doses. SOOPR lasts up to 24 hours and is more effective against synthetic opioids (e.g., fentanyl, nitazenes) than todays standard-of-care Elysium has a highly attractive risk/reward profile: 1. High-probability of Success: In vitro and in vivo proof-of-concept data for its new chemical entities that are comprised of FDA-approved drugs 2. Capital Efficiency: Leveraging non-dilutive grant funding, ~$16M to-date 3. Platform Opportunity: Diversified portfolio of programs addressing the key underlying factors that are driving the opioid crisis and could yield multiple products within 3-5 years 4. Market: Multi-billion-dollar market potential, with weak direct pipeline competition 5. Intellectual Property: Strong protection, with issued patents in the US and internationally, including composition of matter
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
CEO at Elysium Therapeutics
Sign in to CIENCE GO Data to uncover contact details
Free credits every month